|VLP Flu Vaccine||Phase II||Investor||None|
Medicago is a clinical-stage biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs). Medicago’s VLP manufacturing technology is based on a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has the potential to offer speed and cost advantages over competitive technologies. It can deliver a vaccine for testing in less than a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Medicago’s VLPs resemble a virus, allowing them to be recognized readily by the immune system however they lack the core genetic material, making them non-infectious and unable to replicate. The Company is using tobacco leaves to produce pandemic and seasonal influenza VLP vaccines for clinical testing. Medicago is also developing non-influenza vaccine candidates using this innovative plant-derived VLP platform.
1020 Route de l’Église, Office 600
Telephone: (418) 658-9393
Fax: (418) 658-6699